MYC and small cell lung carcinoma: However, the mechanism underlying the sensitivity to platinum and PARis in SCLC-P is not completely known, given that in this subtype the expression of FLN11 is poor, just as the activation of the MYC pathway is not entirely clear given that its activation in SCLC-N is associated with sensitivity to Aurora-kinase-inhibitors (AKIs) while in SCLC-P it is not.